Skip to content
Disclosery

Consonance Capital Management LP

Follow

13F filer, CIK 1544773, New York, NY

Consonance Capital Management LP reported $7,280,000 across 2 holdings for the quarter ended 2022-09-30, in a 13F-HR filed 2022-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001085146-22-004054

Period
2022-09-30
Reported value
$7.28M
Holdings
2
Top 10 weight
100%
New
0
Sold out
5

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
SLNexited-634,270-$7.52M
CMPXexited-1,603,789-$4.22M
UTHRexited-2,998-$706K
GMEDexited-5,405-$303K
TNDMexited-4,294-$254K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2022

Share positions as resolved from 13F-HR 0001085146-22-004054, largest first. % of portfolio is the value over $7,280,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
Surrozen, Inc.Surrozen, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: not reported; 2021Q3: 1,000,000 shares; 2021Q4: 3,497,500 shares; 2022Q1: 3,497,500 shares; 2022Q2: 3,497,500 shares; 2022Q3: 3,497,500 shares 3,497,500$7.07M97.05%0
SRZNWSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: not reported; 2021Q3: 333,333 shares; 2021Q4: 1,165,832 shares; 2022Q1: 1,165,832 shares; 2022Q2: 1,165,832 shares; 2022Q3: 1,165,832 shares 1,165,832$215K2.95%0Timeline

Sold out in Q3 2022

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
SLNSILENCE THERAPEUTICS PLC634,270$7.52Mshares
CMPXCOMPASS THERAPEUTICS INC1,603,789$4.22Mshares
UTHRUNITED THERAPEUTICS CORP DEL2,998$706Kshares
GMEDGLOBUS MED INC5,405$303Kshares
TNDMTANDEM DIABETES CARE INC4,294$254Kshares

How Q3 2022 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001085146-22-004054 base2022-11-14acceptance time not in the bulk data set